Vancity Investment Management Ltd Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Vancity Investment Management Ltd acquired 129,229 shares of Edwards Lifesciences Corporation, valued at approximately $9.37 million, making it the 26th largest holding in their portfolio.
• Insider transactions included Larry L. Wood selling 8,950 shares, decreasing his position by 4.15%, while VP Daniel J. Lippis sold 4,114 shares, reflecting a 15.75% decrease in his ownership.
• Edwards Lifesciences reported earnings of $0.67 per share for the last quarter, surpassing expectations, and set guidance for Q3 2025 at 0.540-0.60 EPS.

Vancity Investment Management Ltd bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 129,229 shares of the medical research company's stock, valued at approximately $9,367,000. Edwards Lifesciences makes up 1.3% of Vancity Investment Management Ltd's portfolio, making the stock its 26th biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $27,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $29,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $29,000. Institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on EW. Barclays upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a research report on Tuesday, July 29th. Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Mizuho increased their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Finally, Morgan Stanley increased their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $86.26.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock worth $1,698,844 over the last quarter. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.51 during trading on Friday, hitting $77.50. 6,301,589 shares of the company's stock traded hands, compared to its average volume of 3,595,766. The stock has a market capitalization of $45.50 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The business has a 50 day moving average of $78.92 and a 200-day moving average of $75.39.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.70 earnings per share. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.